Scholarlink

Purpose <p>Oxygen–ozone (O<sub>2</sub>–O<sub>3</sub>) therapy is increasingly recognized as a minimally invasive option for managing low back pain (LBP). This study aims to assess the efficacy and safety of CT-guided O<sub>2</sub>–O<sub>3</sub> injections, both as a standalone therapy and in combination with other medications, across a diverse cohort of patients with LBP.</p> Materials and methods <p>We conducted a single-center retrospective observational study of patients with LBP who underwent CT-guided O<sub>2</sub>–O<sub>3</sub> intradiscal and/or facet joint injections between January 2016 and March 2017. Patients were categorized into three groups: Group A (facet joint osteoarthritis), Group B (single-level disc herniation with unilateral sciatica), and Group C (double-level disc herniation with bilateral or unilateral sciatica). Pain intensity was assessed using the Visual Analog Scale (VAS) at baseline and three weeks after the final injection. Statistical analysis included paired t-tests for pre- and post-treatment comparisons and one-way ANOVA with Tukey’s HSD for group comparisons.</p> Results <p>A total of 123 patients were included. The mean baseline VAS score for the entire cohort was 7.5 ± 1.2, which significantly decreased to 3.5 ± 1.5 following treatment (T = 43.74, <i>p</i> &lt; 0.001). In Group A, the mean VAS decreased from 7.2 ± 1.3 to 3.8 ± 1.4; in Group B, from 7.8 ± 1.0 to 3.2 ± 1.3; and in Group C, from 8.0 ± 0.9 to 3.0 ± 1.2. ANOVA revealed significant differences in post-treatment VAS scores among groups (F = 27.36, <i>p</i> &lt; 0.001). Tukey’s HSD indicated significant differences between Groups A and B (<i>p</i> &lt; 0.001) and A and C (<i>p</i> &lt; 0.001), with no significant difference between Groups B and C (<i>p</i> = 0.247). Overall, 21.95% of patients experienced significant improvement (VAS reduction &gt; 4 points), 57.72% had moderate improvement (VAS reduction 2–4 points), and 18.7% showed minimal improvement (VAS reduction ≤ 1 point). No complications were reported during or after the procedures.</p> Conclusion <p>The findings strongly support the efficacy and safety of O<sub>2</sub>–O<sub>3</sub> therapy for the treatment of LBP, offering significant short-term pain relief across diverse patient subgroups. Further controlled studies are warranted to confirm long-term efficacy and optimize treatment protocols.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of CT-guided oxygen–ozone (O2–O3) therapy for low back pain: a retrospective single-center study

  • 期刊论文

  • 发表日期：

    2025年8月14日

查看全文
  • Alberto Bellelli,
  • Valerio D’Andrea,
  • Matteo Pileri,
  • Bruno Beomonte Zobel

摘要

Purpose

Oxygen–ozone (O2–O3) therapy is increasingly recognized as a minimally invasive option for managing low back pain (LBP). This study aims to assess the efficacy and safety of CT-guided O2–O3 injections, both as a standalone therapy and in combination with other medications, across a diverse cohort of patients with LBP.

Materials and methods

We conducted a single-center retrospective observational study of patients with LBP who underwent CT-guided O2–O3 intradiscal and/or facet joint injections between January 2016 and March 2017. Patients were categorized into three groups: Group A (facet joint osteoarthritis), Group B (single-level disc herniation with unilateral sciatica), and Group C (double-level disc herniation with bilateral or unilateral sciatica). Pain intensity was assessed using the Visual Analog Scale (VAS) at baseline and three weeks after the final injection. Statistical analysis included paired t-tests for pre- and post-treatment comparisons and one-way ANOVA with Tukey’s HSD for group comparisons.

Results

A total of 123 patients were included. The mean baseline VAS score for the entire cohort was 7.5 ± 1.2, which significantly decreased to 3.5 ± 1.5 following treatment (T = 43.74, p < 0.001). In Group A, the mean VAS decreased from 7.2 ± 1.3 to 3.8 ± 1.4; in Group B, from 7.8 ± 1.0 to 3.2 ± 1.3; and in Group C, from 8.0 ± 0.9 to 3.0 ± 1.2. ANOVA revealed significant differences in post-treatment VAS scores among groups (F = 27.36, p < 0.001). Tukey’s HSD indicated significant differences between Groups A and B (p < 0.001) and A and C (p < 0.001), with no significant difference between Groups B and C (p = 0.247). Overall, 21.95% of patients experienced significant improvement (VAS reduction > 4 points), 57.72% had moderate improvement (VAS reduction 2–4 points), and 18.7% showed minimal improvement (VAS reduction ≤ 1 point). No complications were reported during or after the procedures.

Conclusion

The findings strongly support the efficacy and safety of O2–O3 therapy for the treatment of LBP, offering significant short-term pain relief across diverse patient subgroups. Further controlled studies are warranted to confirm long-term efficacy and optimize treatment protocols.